Assuntos
Endocardite Bacteriana/complicações , Micrococcus luteus/patogenicidade , Infarto Pulmonar/diagnóstico por imagem , Infarto Pulmonar/microbiologia , Antibacterianos/uso terapêutico , Criança , Endocardite Bacteriana/diagnóstico , Endocardite Bacteriana/tratamento farmacológico , Feminino , Humanos , Micrococcus luteus/isolamento & purificação , Infarto Pulmonar/tratamento farmacológico , Infarto Pulmonar/etiologia , Tomografia Computadorizada por Raios XRESUMO
A 59-year-old woman presented with a sudden onset of breathlessness and chest pain. An echocardiography and CT scan showed pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria. For haemodynamically stable patients, the optimal management strategy is poorly defined. Three main strategies were considered: surgical thrombectomy, thrombolysis and anticoagulation. Surgery with reversal of anticoagulation may lead to further coagulation and increased risk of bleeding complications. The significant pulmonary hypertension and right ventricular infarction raised the prospect of difficult weaning from cardiopulmonary bypass following thrombectomy. Thrombolysis, which has significant mortality rate, and systemic embolisation including pulmonary infarction with haemorrhagic transformation were also contraindications. A multidisciplinary approach was adopted and anticoagulation was therefore believed to be the safest and effective approach. Here, the use of anticoagulation alone was fortunately successful but could as easily end in disaster. This approach should be considered the ideal paradigm to yield optimum outcomes.
Assuntos
Anticoagulantes/uso terapêutico , Cardiopatias/tratamento farmacológico , Embolia Pulmonar/tratamento farmacológico , Trombose/tratamento farmacológico , Angiografia por Tomografia Computadorizada , Quimioterapia Combinada , Embolia Paradoxal/diagnóstico por imagem , Embolia Paradoxal/tratamento farmacológico , Feminino , Átrios do Coração , Cardiopatias/diagnóstico por imagem , Heparina/uso terapêutico , Humanos , Pessoa de Meia-Idade , Embolia Pulmonar/diagnóstico por imagem , Infarto Pulmonar/diagnóstico por imagem , Infarto Pulmonar/tratamento farmacológico , Trombose/diagnóstico por imagem , Resultado do Tratamento , Varfarina/uso terapêuticoAssuntos
Embolia Pulmonar/diagnóstico por imagem , Infarto Pulmonar/diagnóstico por imagem , Idoso , Anticoagulantes/uso terapêutico , Dor no Peito/etiologia , Tosse/etiologia , Feminino , Hemoptise/etiologia , Heparina/uso terapêutico , Humanos , Embolia Pulmonar/complicações , Embolia Pulmonar/tratamento farmacológico , Infarto Pulmonar/complicações , Infarto Pulmonar/tratamento farmacológico , Radiografia Torácica , Tomografia Computadorizada por Raios XAssuntos
Anticoagulantes/uso terapêutico , Dor no Flanco/etiologia , Heparina/uso terapêutico , Embolia Pulmonar/complicações , Embolia Pulmonar/diagnóstico por imagem , Infarto Pulmonar/diagnóstico por imagem , Analgésicos Opioides , Anti-Inflamatórios não Esteroides , Diagnóstico Diferencial , Dor no Flanco/tratamento farmacológico , Humanos , Cetorolaco , Masculino , Pessoa de Meia-Idade , Morfina , Artéria Pulmonar/diagnóstico por imagem , Embolia Pulmonar/tratamento farmacológico , Infarto Pulmonar/complicações , Infarto Pulmonar/tratamento farmacológico , Cloreto de Sódio , Tomografia Computadorizada por Raios XRESUMO
Esophageal duplication cyst is a rare congenital mediastinal cyst. Most of these cysts become symptomatic in childhood and only rare cases remain asymptomatic until adolescence. They may produce symptoms due to esophageal and respiratory system compression, rupture, and infection. A 25-year-old man presented with pulmonary infection and bronchiectasis that did not improve with medical treatment. A diagnosis of esophageal duplication cyst was made intraoperatively.
Assuntos
Bronquiectasia/etiologia , Cisto Esofágico/diagnóstico , Esôfago/anormalidades , Infarto Pulmonar/etiologia , Doenças Raras/diagnóstico , Toracotomia , Adulto , Anti-Infecciosos/uso terapêutico , Bronquiectasia/tratamento farmacológico , Diagnóstico Diferencial , Cisto Esofágico/complicações , Cisto Esofágico/cirurgia , Esôfago/cirurgia , Humanos , Masculino , Infarto Pulmonar/tratamento farmacológico , Doenças Raras/complicações , Doenças Raras/cirurgia , Falha de TratamentoRESUMO
Tuberculosis (TB), a chronic infectious disease of global importance, is facing the emergence of drug-resistant strains with few new drugs to treat the infection. Pulmonary cavitation, the hallmark of established disease, is associated with very high bacillary burden. Cavitation may lead to delayed sputum culture conversion, emergence of drug resistance, and transmission of the infection. The host immunological reaction to Mycobacterium tuberculosis is implicated in driving the development of TB cavities. TB is characterized by a matrix-degrading phenotype in which the activity of proteolytic matrix metalloproteinases (MMPs) is relatively unopposed by the specific tissue inhibitors of metalloproteinases. Proteases, in particular MMPs, secreted from monocyte-derived cells, neutrophils, and stromal cells, are involved in both cell recruitment and tissue damage and may cause cavitation. MMP activity is augmented by proinflammatory chemokines and cytokines, is tightly regulated by complex signaling paths, and causes matrix destruction. MMP concentrations are elevated in human TB and are closely associated with clinical and radiological markers of lung tissue destruction. Immunomodulatory therapies targeting MMPs in preclinical and clinical trials are potential adjuncts to TB treatment. Strategies targeting patients with cavitary TB have the potential to improve cure rates and reduce disease transmission.
Assuntos
Antituberculosos/uso terapêutico , Imunomodulação/fisiologia , Metaloproteinases da Matriz/efeitos dos fármacos , Mycobacterium tuberculosis/efeitos dos fármacos , Infarto Pulmonar/etiologia , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Pulmonar/tratamento farmacológico , Animais , Antituberculosos/administração & dosagem , Modelos Animais de Doenças , Progressão da Doença , Sistemas de Liberação de Medicamentos , Saúde Global , Humanos , Metaloproteinases da Matriz/análise , Metaloproteinases da Matriz/imunologia , Infarto Pulmonar/tratamento farmacológico , Infarto Pulmonar/imunologia , Tuberculose Resistente a Múltiplos Medicamentos/imunologia , Tuberculose Resistente a Múltiplos Medicamentos/transmissão , Tuberculose Pulmonar/complicações , Tuberculose Pulmonar/imunologiaRESUMO
Patients with chronic diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and diabetes mellitus, are exposed to particular complications that require a careful diagnostic algorithm. Pulmonary Embolism (PE) in COPD patients often demands an accurate differential diagnosis and a prompt therapeutic intervention. Aspergillus spp. infection comprises a large spectrum of pathological manifestations, depending on immune status and the presence of underlying lung disease. These manifestations may range from invasive pulmonary aspergillosis (IPA) in gravely immunocompromised patients, to chronic necrotizing aspergillosis (CNA) in patients with chronic lung diseases and moderately compromised immune systems. Aspergilloma is generally observed in patients with cavitary lung diseases, and allergic bronchopulmonary aspergillosis (ABPA) is reported in patients with hypersensitivity to Aspergillus antigens. We report a case with pulmonary aspergillosis arisen on a pulmonary infarction after PE in a patient with COPD and diabetes mellitus. To date, report with this clinical evolution was not reported in literature. This report is intended to describe an accurate diagnostic path in a complex overlap of different pathological conditions, highlighting the great importance of differential diagnosis and an appropriate diagnostic algorithm. In addition, open issues on the real diagnostic value of clinical, radiological, and laboratory features for COPD exacerbation, PE and aspergillosis have been discussed.
Assuntos
Aspergilose Pulmonar Invasiva/etiologia , Doença Pulmonar Obstrutiva Crônica/complicações , Embolia Pulmonar/etiologia , Infarto Pulmonar/etiologia , Idoso de 80 Anos ou mais , Algoritmos , Anticoagulantes/uso terapêutico , Antifúngicos/uso terapêutico , Broncodilatadores/uso terapêutico , Complicações do Diabetes/diagnóstico , Complicações do Diabetes/etiologia , Progressão da Doença , Humanos , Aspergilose Pulmonar Invasiva/diagnóstico , Aspergilose Pulmonar Invasiva/tratamento farmacológico , Aspergilose Pulmonar Invasiva/microbiologia , Masculino , Valor Preditivo dos Testes , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/tratamento farmacológico , Infarto Pulmonar/diagnóstico , Infarto Pulmonar/tratamento farmacológico , Fatores de Risco , Esteroides/uso terapêutico , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Trombose Venosa/complicações , Trombose Venosa/diagnósticoRESUMO
Prostacyclin and its analogues (prostanoids) are potent vasodilators, and exhibit antithrombotic, antiproliferative and anti-inflammatory properties. Pulmonary arterial hypertension (PAH) is characterised by vasoconstriction, thrombosis and proliferation, and is associated with reduced synthesis of endogenous prostacyclin. This provides a strong rationale for the use of prostanoids to treat PAH, a concept that is now supported by more than two decades of clinical research and experience. Intravenous and subcutaneous prostanoids have clearly demonstrated efficacy in severe PAH, but adverse events related to the drug delivery system, systemic side-effects and tachyphylaxis have driven research into alternative prostanoid treatments. Iloprost is administered by inhalation, and thus avoids most of the systemic side-effects associated with i.v. or subcutaneous prostanoid infusion. Two randomised controlled 12-week trials in patients with PAH have demonstrated efficacy and a favourable safety profile for iloprost as monotherapy (the AIR trial) and in combination with oral bosentan (STEP). Open-label uncontrolled long-term studies of inhaled iloprost therapy indicate that this treatment may improve long-term outcomes in PAH.